Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/10/2020
SIETES contiene 93128 citas

 
 
 1 a 20 de 282 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Doshi P, Topol E. These coronavirus trials don’t answer the one question we need to know. N Y Times (Print) 2020:22 de septiembre. [Ref.ID 103722]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moynihan R, MacDonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ 2020;369:24 de junio. [Ref.ID 103680]
3. Cita con resumen
Mathieson S, Lin C-WC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ 2020;369:28 de abril. [Ref.ID 103627]
4. Cita con resumen
Mazzucato M, Torreele E. Cómo desarrollar una vacuna del Covid-19 para todos . Sinpermiso 2020:3 de mayo. [Ref.ID 103607]
5. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
6.Enlace a cita original Cita con resumen
Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Ospina NS, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ 2019;365:14 de mayo. [Ref.ID 103122]
7.Enlace a cita original Cita con resumen
Khan MS, Lateef N, Siddiqi TJ, Rehmab KA, Alnaimat S, Khan SU, Riaz H, Murad H, Mandrola J, Doukky R, Krasuski RA. Level and prevalence of spin in published cardiovascular randomized clinical trial reports with statistically nonsignificant primary outcomes. A systematic review. JAMA Network Open 2019:3 de mayo. [Ref.ID 103114]
8.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]
9.Tiene citas relacionadas Cita con resumen
Zeng C, Dubreuil M, LaRochelle MR, Lu N, Wei J, Choi HK, Lei G, Zhang Y. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA 2019;321:12 de marzo. [Ref.ID 103057]
10.Enlace a cita original Cita con resumen
Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]
11.Enlace a cita original Cita con resumen
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]
12. Cita con resumen
Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al.. Opioids for chronic noncancer pain. A systematic review and meta-analysis. JAMA 2018;320:18 de diciembre. [Ref.ID 102914]
13.Enlace a cita original Cita con resumen
Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]
14.Enlace a cita original Cita con resumen
Hernández-Aguado I, Chilet-Rosell E. Pathways of undue influence in health policy-making: a main actor's perspective. J Epidemiol Community Health 2018;72:154-9. [Ref.ID 102446]
15. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
16. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
17.Tiene citas relacionadas Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
18.Tiene citas relacionadas Cita con resumen
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016:28 de junio. [Ref.ID 100445]
19. Cita con resumen
Garattini S. The European Medicines Agency is still too close to industry. BMJ 2016;353:i2412. [Ref.ID 100360]
20. Cita con resumen
Boussageon R, Gueyffier F, Cornu C. Metformin as firstline treatment for type 2 diabetes: are we sure?. BMJ 2016;352:h6748. [Ref.ID 99967]
Seleccionar todas
 
 1 a 20 de 282 siguiente >>